GlassScriptPhysician profile
Lisa Ditchey
NPI 1750777231
$3,803.57
in general payments reported to CMS, 2019-2025
36 companies · $643 in 2025
The $643 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $463 · 2022: $225 · 2023: $979 · 2024: $1,052 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,674.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $714.59 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $544.37 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $335.39 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $254.61 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.24 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $180.17 | 2019-2025 | Trelegy Ellipta, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.63 | 2020-2025 | Ofev, Jardiance |
| Daiichi Sankyo INC. | $134.55 | 2023-2025 | Injectafer |
| Pfizer INC. | $133.08 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $115.42 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Amgen INC. | $115.00 | 2019-2025 | Evenity, Krystexxa |
| Xeris Pharmaceuticals, INC. | $70.38 | 2022-2025 | Gvoke Hypopen, Keveyis |
| Astellas Pharma US INC | $69.42 | 2023-2024 | Veozah, Myrbetriq |
| Edwards Lifesciences Corporation | $68.65 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Dexcom, INC. | $64.22 | 2022-2023 | Dexcom G6 Transmitter |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Ditchey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.